AbbVie : Allergan Seeks FDA OK of AGN-190584 in Presbyopia

By Colin Kellaher

AbbVie Inc.'s Allergan unit on Thursday said it filed a new-drug application with the U.S. Food and Drug Administration for AGN-190584, an ophthalmic solution for the treatment of the common vision condition presbyopia.

Allergan said AGN-190584, if approved, would be the first eye drop to treat presbyopia, a progressive condition that reduces the eye's ability to focus on near objects and usually impacts people after age 40.

Allergan, which noted that roughly 128 million adults in the U.S. experience presbyopia, said it expects the FDA to act on the application by the end of the year.

Write to Colin Kellaher at [e-mail]

(END) Dow Jones Newswires

02-25-21 0843ET